Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-248 in Relapsed/Refractory Multiple Myeloma
NCT06668792Phase 2
Key facts
- Status
- Recruiting
- Start
- Dec 2024
- Primary completion
- Feb 2026
- Countries
- 1
- Sponsor
- BIOCAD
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Drugs
- BCD-248
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, open-label, single-arm trial of BCD-248 in multiple myeloma (MM), sponsored by BIOCAD. Primary endpoint: Overall Response Rate at 24 weeks. Started Dec 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
BCD-248
Experimental arm receiving BCD-248
03
Who it enrols
Patients aged 18+ with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapy (including PI, IMiD, anti-CD38) and have not received prior anti-BCMA or anti-CD3 therapy.
04
Endpoints
Primary
Overall Response Rate
Secondary
Progression-Free Survival
Complete Response Rate
Minimal Residual Disease Negativity Rate
Duration of Response
Time to Progression
Time to Response
Overall Survival
Incidence and Characteristics of Adverse Events
Beyond the preview
Go deeper on NCT06668792.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668792.